Edition:
United Kingdom

Pfizer's Lyrica Fails to Meet Main Goal in Late-stage Epilepsy Study


Friday, 24 May 2019 

May 24 (Reuters) - Pfizer Inc ::PFIZER ANNOUNCES TOP-LINE RESULTS FROM PHASE 3 TRIAL OF LYRICA® (PREGABALIN) IN PRIMARY GENERALIZED TONIC-CLONIC SEIZURES.PFIZER INC - TREATMENT WITH LYRICA DID NOT RESULT IN A STATISTICALLY SIGNIFICANT REDUCTION IN SEIZURE FREQUENCY VERSUS PLACEBO.PFIZER INC - STUDY DID NOT MEET ITS PRIMARY ENDPOINT.PFIZER INC - SAFETY PROFILE OBSERVED IN PHASE 3 STUDY WAS COMPARABLE TO KNOWN PROFILE OF LYRICA IN PRIOR EPILEPSY STUDIES.